ArticleJournal of biomedicine & biotechnology2012
Distinct effects of contraction-induced injury in vivo on four different murine models of dysferlinopathy.
Article in Journal of biomedicine & biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Open-Source Tools for Neuromuscular Electrical Stimulation in Mouse Models: A Methodological Validation Study.Muscles (Basel, Switzerland) · 2026Article
- Dysferlin and the Regulation of CaCells · 2025Review
- Dosage-Adjusted Resistance Training in Mice with a Reduced Risk of Muscle Damage.Journal of visualized experiments : JoVE · 2022Article
- Phospholipids: Identification and Implication in Muscle Pathophysiology.International journal of molecular sciences · 2021Review
- Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy.Experimental neurology · 2019Article
- Functional muscle hypertrophy by increased insulin-like growth factor 1 does not require dysferlin.Muscle & nerve · 2019Article
- Dysferlin-deficiency has greater impact on function of slow muscles, compared with fast, in aged BLAJ mice.PloS one · 2019Article
- Diltiazem improves contractile properties of skeletal muscle in dysferlin-deficient BLAJ mice, but does not reduce contraction-induced muscle damage.Physiological reports · 2018Article
- Effect of Ibuprofen on Skeletal Muscle of Dysferlin-Null Mice.The Journal of pharmacology and experimental therapeutics · 2018Article
- Myofiber damage precedes macrophage infiltration after in vivo injury in dysferlin-deficient A/J mouse skeletal muscle.The American journal of pathology · 2015Article
- Myopathic changes in murine skeletal muscle lacking synemin.American journal of physiology. Cell physiology · 2015Article
- Improved immunoblotting methods provide critical insights into phenotypic differences between two murine dysferlinopathy models.Muscle & nerve · 2014Article
- Dysferlin at transverse tubules regulates Ca(2+) homeostasis in skeletal muscle.Frontiers in physiology · 2014Review
- Dysferlin stabilizes stress-induced Ca2+ signaling in the transverse tubule membrane.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Yoga as an Adjunctive Intervention for Duchenne Muscular Dystrophy: A Scoping Review.International journal of yogaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in the DYSF gene, encoding dysferlin, cause muscular dystrophies in man. We compared 4 dysferlinopathic mouse strains: SJL/J and B10.SJL-Dysf(im)/AwaJ (B10.SJL), and A/J and B6.A-Dysf(prmd)/GeneJ (B6.A/J). The former but not the latter two are overtly myopathic and weaker at 3 months of age. Following repetitive large-strain injury (LSI) caused by lengthening contractions, all except B6.A/J showed ~40% loss in contractile torque. Three days later, torque in SJL/J, B10.SJL and controls, but not A/J, recovered nearly completely. B6.A/J showed ~30% torque loss post-LSI and more variable recovery. Pre-injury, all dysferlinopathic strains had more centrally nucleated fibers (CNFs) and all but A/J showed more inflammation than controls. At D3, all dysferlinopathic strains showed increased necrosis and inflammation, but not more CNFs; controls were unchanged. Dystrophin-null DMD(mdx) mice showed more necrosis and inflammation than all dysferlin-nulls. Torque loss and inflammation on D3 across all strains were linearly related to necrosis. Our results suggest that (1) dysferlin is not required for functional recovery 3 days after LSI; (2) B6.A/J mice recover from LSI erratically; (3) SJL/J and B10.SJL muscles recover rapidly, perhaps due to ongoing myopathy; (4) although they recover function to different levels, all 4 dysferlinopathic strains show increased inflammation and necrosis 3 days after LSI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.